US2016193316A1PendingUtilityA1

Inducing Cellular Immune Responses to Plasmodium Falciparum Using Peptide and Nucleic Acid Compositions

48
Assignee: EPIMMUNE INCPriority: Mar 5, 1993Filed: Dec 28, 2015Published: Jul 7, 2016
Est. expiryMar 5, 2013(expired)· nominal 20-yr term from priority
Inventors:Alessandro SetteJohn SidneyScott SouthwoodBrian D. LivingstonRobert ChestnutDenise BakerEsteban CelisRalph T. KuboHoward Grey
C12N 2770/24222C12N 2740/16222A61K 2039/55566A61K 2039/57C12N 2740/16122C12N 2730/10122C07K 14/005C12N 2740/16322C07K 14/445C07K 7/08A61K 2039/605A61K 39/015C07K 2319/01C07K 2319/00A61K 39/002A61K 2039/572C07K 14/70539A61K 40/438A61K 40/42A61K 40/11Y02A50/30
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare Plasmodium falciparum epitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria. In particular, this application discloses isolated peptides comprising oligopeptides, for example the oligopeptides LLACAGLAY, FLIFFDLFLV, FMKAVCVEV, VLAGLLGNV, GLIMVLSFL, KILSVFFLA, GLLGNVSTV, VLLGGVGLVL, ILSVSSFLFV, QTNFKSLLR, LACAGLAYK, ALFFIIFNK, LLACAGLAYK, HVLSHNSYEK, FILVNLLIFH, FQDEENIGIY, PSDGKCNLY, YYIPHQSSL, FYFILVNLL, KYLVIVFLI and KYKLATSVL, or isolated peptides conjugated with T helper peptides that are used as antigens in epitope-based vaccines to prevent and/or treat malaria.

Claims

exact text as granted — not AI-modified
1 - 40 . (canceled) 
     
     
         41 . An isolated peptide less than 13 amino acids in length comprising the oligopeptide: LLACAGLAY (SEQ ID NO: 3019), FLIFFDLFLV (SEQ ID NO: 3718), FMKAVCVEV (SEQ ID NO: 3719), VLAGLLGNV (SEQ ID NO: 3720), GLIMVLSFL (SEQ ID NO: 3721), KILSVFFLA (SEQ ID NO: 3722), GLLGNVSTV (SEQ ID NO: 3723), VLLGGVGLVL (SEQ ID NO: 3724), ILSVSSFLFV (SEQ ID NO: 3725), QTNFKSLLR (SEQ ID NO: 3726), LACAGLAYK (SEQ ID NO: 3727), ALFFIIFNK (SEQ ID NO: 3729), LLACAGLAYK (SEQ ID NO: 3730), HVLSHNSYEK (SEQ ID NO: 3732), FILVNLLIFH (SEQ ID NO: 3733), FQDEENIGIY (SEQ ID NO: 3737), PSDGKCNLY (SEQ ID NO: 3739), YYIPHQSSL (SEQ ID NO: 3740), FYFILVNLL (SEQ ID NO: 3741), KYLVIVFLI (SEQ ID NO: 3742) or KYKLATSVL (SEQ ID NO: 3743). 
     
     
         42 . The isolated peptide of  claim 41 , wherein the peptide is LLACAGLAY (SEQ ID NO: 3019), FLIFFDLFLV (SEQ ID NO: 3718), FMKAVCVEV (SEQ ID NO: 3719), VLAGLLGNV (SEQ ID NO: 3720), GLIMVLSFL (SEQ ID NO: 3721), KILSVFFLA (SEQ ID NO: 3722), GLLGNVSTV (SEQ ID NO: 3723), VLLGGVGLVL (SEQ ID NO: 3724), ILSVSSFLFV (SEQ ID NO: 3725), QTNFKSLLR (SEQ ID NO: 3726), LACAGLAYK (SEQ ID NO: 3727), ALFFIIFNK (SEQ ID NO: 3729), LLACAGLAYK (SEQ ID NO: 3730), HVLSHNSYEK (SEQ ID NO: 3732), FILVNLLIFH (SEQ ID NO: 3733), FQDEENIGIY (SEQ ID NO: 3737), PSDGKCNLY (SEQ ID NO: 3739), YYIPHQSSL (SEQ ID NO: 3740), FYFILVNLL (SEQ ID NO: 3741), KYLVIVFLI (SEQ ID NO: 3742) or KYKLATSVL (SEQ ID NO: 3743). 
     
     
         43 . A conjugate of an isolated peptide less than 13 amino acids in length comprising an oligopeptide selected from a group consisting of LLACAGLAY (SEQ ID NO: 3019), FLIFFDLFLV (SEQ ID NO: 3718), FMKAVCVEV (SEQ ID NO: 3719), VLAGLLGNV (SEQ ID NO: 3720), GLIMVLSFL (SEQ ID NO: 3721), KILSVFFLA (SEQ ID NO: 3722), GLLGNVSTV (SEQ ID NO: 3723), VLLGGVGLVL (SEQ ID NO: 3724), ILSVSSFLFV (SEQ ID NO: 3725), QTNFKSLLR (SEQ ID NO: 3726), LACAGLAYK (SEQ ID NO: 3727), ALFFIIFNK (SEQ ID NO: 3729), LLACAGLAYK (SEQ ID NO: 3730), HVLSHNSYEK (SEQ ID NO: 3732), FILVNLLIFH (SEQ ID NO: 3733), FQDEENIGIY (SEQ ID NO: 3737), PSDGKCNLY (SEQ ID NO: 3739), YYIPHQSSL (SEQ ID NO: 3740), FYFILVNLL (SEQ ID NO: 3741), KYLVIVFLI (SES ID NO: 3742) and KYKLATSVL (SEQ ID NO: 3743) and a T helper peptide, wherein the T helper peptide is less than about 50 amino acids in length and wherein the T helper peptide comprises a pan-DR binding epitope. 
     
     
         44 . The conjugate of  claim 43 , wherein the isolated peptide is LLACAGLAY (SEQ ID NO: 3019), FLIFFDLFLV (SEQ ID NO: 3718), FMKAVCVEV (SEQ ID NO: 3719), VLAGLLGNV (SEQ ID NO: 3720), GLIMVLSFL (SEQ ID NO: 3721), KILSVFFLA (SEQ ID NO: 3722), GLLGNVSTV (SEQ ID NO: 3723), VLLGGVGLVL (SEQ ID NO: 3724), ILSVSSFLFV (SEQ ID NO: 3725), QTNFKSLLR (SEQ ID NO: 3726), LACAGLAYK (SEQ ID NO: 3727), ALFFIIFNK (SEQ ID NO: 3729), LLACAGLAYK (SEQ ID NO: 3730), HVLSHNSYEK (SEQ ID NO: 3732), FILVNLLIFH (SEQ ID NO: 3733), FQDEENIGIY (SEQ ID NO: 3737), PSDGKCNLY (SEQ ID NO: 3739), YYIPHQSSL (SEQ ID NO: 3740), FYFILVNLL (SEQ ID NO: 3741), KYLVIVFLI (SEQ ID NO: 3742) or KYKLATSVL (SEQ ID NO: 3743). 
     
     
         45 . The conjugate of  claim 43 , wherein said pan-DR binding epitope is aKXVWANTLKAAa (SEQ ID NO: 3802), wherein “X” is either cycloexylalanine, phenylalanine, or tyrosine, and “a” is either D-alanine or L-alanine. 
     
     
         46 . The conjugate of  claim 45 , wherein “X” is cycloexylalanine. 
     
     
         47 . The conjugate of  claim 45 , wherein “X” is phenylalanine. 
     
     
         48 . The conjugate of  claim 45 , wherein “X” is tyrosine. 
     
     
         49 . The conjugate of  claim 45 , wherein “a” is D-alanine. 
     
     
         50 . The conjugate of  claim 45 , wherein “a” is L-alanine. 
     
     
         51 . A composition comprising the isolated peptide of  claim 41 . 
     
     
         52 . A composition comprising the isolated peptide  claim 42 . 
     
     
         53 . The composition of  claim 51 , further comprising a carrier. 
     
     
         54 . A composition comprising the conjugate of  claim 43 . 
     
     
         55 . A composition comprising the conjugate of  claim 44 . 
     
     
         56 . The composition of  claim 54 , further comprising a carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.